

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/227096 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/74 (2006.01)
C07K 14/725 (2006.01) C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2024/026671

(22) International Filing Date:

26 April 2024 (26.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/462,957	28 April 2023 (28.04.2023)	US
63/507,064	08 June 2023 (08.06.2023)	US
63/589,286	10 October 2023 (10.10.2023)	US
63/595,230	01 November 2023 (01.11.2023)	US
63/618,817	08 January 2024 (08.01.2024)	US

(71) Applicant: **SANA BIOTECHNOLOGY, INC.** [US/US];
188 East Blaine Street, Suite 400, Seattle, Washington
98102 (US).

(72) Inventors: **KOUROS-MEHR, Hosein**; c/o Sana Biotech-
nology, Inc., 188 East Blaine Street, Suite 400, Seattle,
Washington 98102 (US). **BRUNETTA, Paul**; c/o Sana
Biotechnology, Inc., 188 East Blaine Street, Suite 400, Seat-

tle, Washington 98102 (US). **DAHILL, Diane Marie**; c/o
Sana Biotechnology, Inc., 188 East Blaine Street, Suite 400,
Seattle, Washington 98102 (US). **BOWDEN, Alexandra**;
c/o Sana Biotechnology, Inc., 188 East Blaine Street, Suite
400, Seattle, Washington 98102 (US).

(74) Agent: **BYCHOWSKI, Meaghan E.** et al.; CHOATE,
HALL & STEWART LLP, Two International Place, Boston,
Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ANTI-CD19 CAR T CELLS FOR TREATING B-CELL MALIGNANCIES AND AUTOIMMUNE DISEASES




Figure 1

(57) Abstract: The present disclosure provides methods of treating a subject having or suspected of having a B cell malignancy or a B cell mediated disorder by administering hypimmune allogenic CD19-directed CAR T cells. Also disclosed are pharmaceutical compositions comprising hypimmune allogenic CD19-directed CAR T cells, for use in treating a subject having or suspected of having a B cell malignancy or a B cell mediated disorder.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*